Physician profile
Ted Lao
NPI 1073007712
$19,438.45
in general payments reported to CMS, 2019-2025
15 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,112 · 2023: $1,493 · 2024: $719 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $15K · Food and Beverage: $2,854 · Travel and Lodging: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $15,000.00 |
| Food and Beverage | $2,854.10 |
| Travel and Lodging | $472.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $15,000.00 | 2025 | Auryon Laser System 100-120 Vac |
| Medtronic, INC. | $1,076.31 | 2023-2025 | Ellipsys Vascular Access System |
| Astrazeneca Pharmaceuticals Lp | $685.67 | 2022 | |
| Aurinia Pharma U.S., INC. | $583.84 | 2022-2024 | Lupkynis |
| Bard Peripheral Vascular, INC. | $404.96 | 2023-2025 | Covera, Venovo, Pristine |
| Travere Therapeutics, INC. | $266.25 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $257.82 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $250.00 | 2023-2025 | Jynarque |
| Globus Medical, INC. | $238.12 | 2025 | Senza |
| Abbott Laboratories | $217.67 | 2024-2025 | Diamondback Coronary, Esprit, Diamondback Peripheral |
| Advanced Oxygen Therapy INC. | $180.67 | 2024 | Topical Oxygen Chamber For Extremities |
| Amgen INC. | $125.00 | 2024 | Krystexxa |
| Horizon Therapeutics Plc | $114.92 | 2022 | |
| Lemaitre Vascular, INC. | $21.08 | 2025 | Lemaitre Embolectomy Catheter |
| Vifor Pharma, INC. | $16.14 | 2023 | Veltassa, Korsuva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Lao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.